Your browser doesn't support javascript.
loading
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Hebart, Holger; Kiehl, Michael; Tomasek, Jiri; Csoszi, Tibor; Koukakis, Reija; Kafatos, George; Kuhn, Anja; Bjorklof, Katja; Demonty, Gaston; Buchler, Tomas.
Afiliação
  • Hebart H; Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany. Holger.Hebart@kliniken-ostalb.de.
  • Kiehl M; Medical Clinic I, Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany.
  • Tomasek J; Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Csoszi T; Oncology Department, Hetenyi G. County Hospital, Szolnok, Hungary.
  • Koukakis R; Department of Biostatistics, Amgen Ltd, Uxbridge, UK.
  • Kafatos G; Center for Observational Research, Amgen Ltd, Uxbridge, UK.
  • Kuhn A; Research and Development, Amgen GmbH, Munich, Germany.
  • Bjorklof K; EU Medical Affairs, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
  • Demonty G; Medical Development, Amgen, Brussels, Belgium.
  • Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
Adv Ther ; 36(3): 670-683, 2019 03.
Article em En | MEDLINE | ID: mdl-30689133

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Panitumumabe Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Panitumumabe Idioma: En Ano de publicação: 2019 Tipo de documento: Article